ArticleInternational journal of general medicine2026
Assessing the Lower Incidence of Invasive Pneumococcal Diseases in Japan During the COVOD-19 Pandemic.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the COVID-19 pandemic from 2020 to 2023 in Japan, in our hospital there were seven cases of invasive pneumococcal diseases (IPDs) in this COVID-19 pandemic period although 14 IPD cases were treated in 2019, 2024, and 2025, such as pre-/post- COVID-19 pandemic period. Of these total 21 IPD patients, five (23.8%) died, and they were all treated during pre-/post-pandemic period. Only 2 of the 21 patients (9.5%) children had been vaccinated. Furthermore, compared with survivors, those who died were younger (54.0 vs 69.4 years old, p = 0.0011), had lower white blood cell counts (3672.1 vs 12117.3/µL, p = 0.0011), and had higher C-reactive protein levels (34.5 vs 22.1 mg/dL, p = 0.0010). Two or more bacteria were isolated, and multiple and/or broad antimicrobial agents were used in fatal cases. These data suggested that IPD cases decreased and might have been less pathogenic during the COVID-19 pandemic period than in the pre-/post-COVID-19 pandemic period. In addition, those who died were younger, more septic due to multiple bacterial infections, and received more and broader antimicrobial agents than survivors. No adult patients received pneumococcal vaccination, which suggests that low vaccination rates lead to the high mortality of adult IPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.